Pacific Biosciences reported Q4 revenue of $44.6 million, up 14% year‑over‑year, driven by a record for consumables and growth across clinical market adoption. The company shipped Revio and Vega instruments and signaled progress toward lowering sequencing costs with a planned SPRQ‑Nx launch. PacBio posted a net loss for the quarter but beat consensus revenue estimates; management highlighted strengthened balance‑sheet positioning after the sale of short‑read assets. The company said 2025 consumables revenue reached an all‑time high and that clinical sequencing placements rose, supporting ongoing adoption in translational and diagnostic labs. Investors will watch the SPRQ‑Nx rollout and the firm’s path to profitability as long‑read sequencing becomes more central to rare‑disease and oncology workflows, where read length and structural variant resolution offer differentiation versus short‑read platforms.